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Tim-3 was initially identified on activated Th1, Th17, and Tc1 cells and induces T cell death
or exhaustion after binding to its ligand, Gal-9. The observed relationship between dys-
regulated Tim-3 expression on T cells and the progression of many clinical diseases has
identified this molecule as an important target for intervention in adaptive immunity. Recent
data have shown that it also plays critical roles in regulating the activities of macrophages,
monocytes, dendritic cells, mast cells, natural killer cells, and endothelial cells. Although the
underlying mechanisms remain unclear, dysregulation ofTim-3 expression on these innate
immune cells leads to an excessive or inhibited inflammatory response and subsequent
autoimmune damage or viral or tumor evasion. In this review, we focus on the expres-
sion and function of Tim-3 on innate immune cells and discuss (1) how Tim-3 is expressed
and regulated on different innate immune cells; (2) how it affects the activity of different
innate immune cells; and (3) how dysregulated Tim-3 expression on innate immune cells
affects adaptive immunity and disease progression.Tim-3 is involved in the optimal activa-
tion of innate immune cells through its varied expression. A better understanding of the
physiopathological role of theTim-3 pathway in innate immunity will shed new light on the
pathogenesis of clinical diseases, such as autoimmune diseases, chronic viral infections,
and cancer, and suggest new approaches to intervention.
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INTRODUCTION
T cell immunoglobulin domain and mucin domain (Tim)-3, ini-
tially identified on terminally differentiated Th1 cells, negatively
regulates the T cell response by inducing T cell apoptosis (1). Tim-
3 was later found to be also present on activated Th17 and Tc1
cells (2–4), and many studies have shown that dysregulation of
Tim-3 expression on CD4+ T cells and CD8+ T cells is closely
related to many autoimmune diseases, viral infections, and cancer
[e.g., (2–4)]. For example, Liberal et al. (2) showed that reduced
levels of Tim-3 on CD4+ T effector cells result in enhanced T cell
activation in patients with autoimmune hepatitis. In contrast, Wu
et al. (3) showed that upregulation of Tim-3 on CD8+ T cells leads
to T cell paralysis in patients with HIV infection.
Recently, Tim-3 was also shown to play important roles on
innate immune cells, including macrophages/monocytes (5–9),
dendritic cells (DCs) (10–13), and natural killer (NK) cells (14–
16). Excessive upregulation of Tim-3 expression on these innate
immune cells was found to lead to exacerbation of clinical diseases
(3, 4, 11, 16). In contrast to the relatively clear mechanisms of Tim-
3-mediated T cell death or exhaustion (1–4), the mechanisms by
which Tim-3 regulates the activities of innate immune cells remain
largely unclear. Here, we will focus on the function of Tim-3 in
some important innate immune cells and how it contributes to
immune homeostasis by regulating their activity.
Abbreviations: DC, dendritic cells; Gal-9, galectin-9; MDSC, myeloid-derived
suppressor cells; Tim-3, T cell immunoglobulin and mucin domain protein 3
Tim-3 IS ACTIVELY INVOLVED IN REGULATING
MACROPHAGE/MONOCYTE ACTIVITY
Macrophages play critical roles in inflammatory responses, and
their dysregulation is associated with excessive or uncontrolled
inflammation. Many regulatory mechanisms exist to maintain
macrophage homeostasis. Recently, Tim-3, a negative immune
regulator of effector T cells, was shown to be involved in the reg-
ulation of macrophage activity (5–7). Monney et al. (5) reported
that the in vivo administration of anti-Tim-3 antibody increased
the number and activation level of macrophages and enhanced
the clinical and pathological severity of experimental autoimmune
encephalomyelitis. Although the underlying mechanisms were not
clearly determined, their data indicated that Tim-3 may negatively
regulate macrophage activation and/or function and thus affect
the progression of autoimmune diseases.
Subsequently, Frisancho-Kiss et al. (6) showed that viral infec-
tion of mice led to rapid Tim-3 expression on macrophages in
the peritoneum, spleen, and heart and that blockade of the Tim-3
pathway led to decreased CD80 expression on macrophages and
an enhanced inflammatory response. These findings suggest that
Tim-3 is involved in the earlier stages of an immune response
and may act as an inhibitor of macrophage activation. Recent
data from our own laboratory shed new light on the roles of
Tim-3 in macrophage activation by showing that Tim-3 expres-
sion on macrophages was unregulated in sepsis or in response to
lipopolysaccharide (LPS) stimulation (7), suggesting that Tim-3
acts as an activation marker. Consistent with the data of Frisancho-
Kiss et al. (6), we also showed that blockade of the Tim-3 pathway
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during sepsis in vivo or downregulation of Tim-3 on macrophages
in vitro led to enhanced macrophage activation (7). Our findings
show that Tim-3 can be upregulated on macrophages in response
to stimuli and that it may also act to suppress macrophage activity.
As regards monocytes, Ma et al. (8, 9, 17) showed that Tim-
3 is constitutively expressed on resting human CD14+ mono-
cytes/macrophages and that it acts to limit IL-12 production. Their
studies demonstrated that stimulation with the Toll-like receptor
4 (TLR4) ligand LPS or the TLR7/8 ligand R848 downregulates
Tim-3 expression, leading to enhanced IL-12 expression, consis-
tent with our previous data in macrophages, which showed that
LPS downregulates the expression of Tim-3 in a dose- and time-
dependent manner, leading to enhanced TNF-α and IL-6 produc-
tion (7). These data suggest that Tim-3 is dynamically expressed on
monocytes/macrophages and that its expression is closely related
to the activity of these cells. However, in patients with chronic
hepatitis C virus (HCV) infection, Tim-3 is overexpressed on
unstimulated and TLR-stimulated monocytes and macrophages
and this is associated with decreased IL-12 expression compared
to healthy subjects (8). A previous report showed that TLR lig-
and stimulation (malaria parasites) resulted in decreased Tim-3
expression on monocytes from HIV (−) controls, but not those
from HIV (+) donors (18). Thus, increased Tim-3 expression on
monocytes may act to suppress their activity, whereas reduced
Tim-3 expression may be associated with monocyte activation.
In such a scenario, increased Tim-3 expression and a failure in
the downregulation of Tim-3 on macrophages/monocytes by fac-
tors such as LPS and TLR4 may act as markers for dysfunctional
macrophages/monocytes, as demonstrated previously for CD4+
and CD8+ T cells (2, 3).
In addition to the role of Tim-3 as a negative regulator of
macrophage activation, blockade of the Tim-3 pathway has been
shown to inhibit the phagocytic potential of uterine macrophages,
resulting in a buildup of apoptotic bodies at the uteroplacental
interface that elicits a local immune response (19), suggesting
that Tim-3 regulates phagocytosis by macrophages. In addition,
a recent study (20) demonstrated that Tim-3 recognizes apoptotic
cells through the FG loop in the IgV domain and is crucial for the
clearance of apoptotic cells by phagocytes. This study also demon-
strated reduced cross-presentation of dying cell-associated anti-
gens following Tim-3 pathway blockade in vitro and in vivo. These
data suggest that Tim-3 contributes to peripheral tolerance by
regulating macrophage-mediated phagocytosis and antigen cross-
presentation. However, it is still unclear how dysregulated Tim-3
expression affects phagocytosis and antigen cross-presentation
and subsequent disease progression.
Dynamic expression of Tim-3 on macrophages is also observed
in autoimmune diseases and is associated with the polarization of
macrophages. Working with an experimental autoimmune neu-
ritis (EAN) model, Zhang et al. (21) showed that, during the
recovery phase, Tim-3 expression is increased on CD68+ and
CD163+ macrophages and that recovery from EAN is accompa-
nied by increased Tim-3 expression on CD163+ cells. In response
to cytokines, resident macrophages, or recruited monocytes differ-
entiate into two distinct subsets referred to as classically activated
(M1) or alternatively activated (M2) macrophages (22, 23). M1
macrophages primarily function to promote inflammation and
tissue damage, whereas M2 macrophages play a major role in
damping down the inflammatory response. As CD163 expres-
sion is upregulated by anti-inflammatory signals (24), high CD163
expression is considered to be a marker for M2 macrophages (25).
The data reported by Zhang et al. (21) suggest that Tim-3 expres-
sion is associated with macrophage polarization and that enhanced
Tim-3 expression on CD163+ macrophages (M2) contributes to
immune regulation by limiting macrophage activation. In agree-
ment with this, Frisancho-Kiss et al. (26) demonstrated that Tim-3
was upregulated on M2 cells in gonadectomized male mice and
mediated an anti-inflammatory response. These data again show
that Tim-3 is kinetically expressed on macrophages and that it
dynamically regulates their activity.
A model can be developed summarizing the expression and
function of Tim-3 on macrophages/monocytes. Tim-3 is consti-
tutively expressed on innate immune cells at a certain level or
its expression can be induced to this level, which we will call
“checkpoint” at which it acts as an activation limiter or “brake.” In
circumstances in which Tim-3 can be normally downregulated, its
“limiter” or “brake” function is suppressed and the cells become
functional; we will call this process “regular activation.” However,
in circumstances, such as chronic inflammation, in which Tim-3
is overexpressed or its expression can no longer be downregu-
lated by factors such as LPS, Tim-3 signaling maintains the cell
in a quiescent state, referred to as “exhaustion” or “dysfunction”
(Figure 1).
Although the above data allow us to propose a functional model
of the involvement of Tim-3 in the regulation of immune cell
activity, three points remain to be determined. First, the factors
that regulate Tim-3 expression in different conditions must be
identified. A partial answer has been provided by data showing
that TLR signaling is involved in the regulation of Tim-3 on
some immune cells (7–9). For example, our previous study (7)
showed that LPS (a TLR4 ligand) can bidirectionally regulate Tim-
3 expression on macrophages, while other data (9) showed that
FIGURE 1 | Model of theTim-3-mediated regulation of innate immune
responses. On innate immune cells, Tim-3 can be either constitutively
expressed at a certain level which we term “checkpoint,” or its expression
can be induced to this level, at which it acts as an activation limiter or
“brake.” When Tim-3 can be normally downregulated, its “limiter” or
“brake” function is suppressed and the cells become functional; we term
this process “regular activation.” However, in circumstances, such as
chronic inflammation, in which Tim-3 is overexpressed or cannot be
downregulated, Tim-3 signaling maintains the cell in a quiescent state,
referred to as “exhaustion” or “dysfunction.” x -axis: stimulation time (h);
y -axis: mean fluorescence intensity (MFI) of Tim-3 on macrophages.
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LPS and R848 (a TLR7/8 ligand) can downregulate Tim-3 expres-
sion on monocytes, which is upregulated in HCV infection (8, 9).
Other factors that contribute to the dynamic expression of Tim-
3 on macrophages/monocytes remain to be identified. Second,
the mechanisms by which Tim-3 regulates macrophage/monocyte
activity are also unclear. As shown in our previous study (7),
Tim-3 signaling increases the LPS-induced phosphorylation of
PI3K-AKT and also the expression of A20, which inhibits NF-κB
activation and subsequent macrophage activation, but the detailed
mechanisms remain to be determined. Third, the mechanisms by
which dysregulated Tim-3 expression on macrophages/monocytes
affects adaptive immunity are not known. Tim-3 expression has
been shown to be associated with the polarization of M1 and
M2 cells. Moreover, M1 polarization is associated with Th1 polar-
ization, and M2 polarization is associated with Th2 polarization
(22, 23). Wang et al. (27) showed that, in HCV-infected patients,
Tim-3 overexpression on monocytes is positively correlated with
IL-23 levels and negatively correlated with IL-12 levels, leading
to a Th17-biased response. These data suggest that Tim-3 also
contributes to the homeostasis of adaptive immunity by affecting
the polarization and/or activity of innate immune cells. However,
the underlying mechanisms remain unclear, including, for exam-
ple, how Tim-3 expression affects the polarization and activity of
macrophages/monocytes, leading to biased T cell polarization.
THE ROLES OF Tim-3 ON DENDRITIC CELLS ARE CONTEXT-DEPENDENT
Recently, Chiba et al. (10) reported that tumor-infiltrating DCs
show increased Tim-3 expression and suppress nucleic-acid-
mediated innate immune responses as a result of the interaction
between Tim-3 and the alarmin HMGB1, and that, when Tim-
3 signaling was blocked using anti-Tim-3 monoclonal antibody,
chemotherapy was found to be more effective, suggesting that
Tim-3 plays a role in tumor pathogenesis. They also reported that,
after stimulation of bone marrow derived DCs (BMDCs) with
nucleic-acid TLR agonists, expression of the cytokines interferon-
β1 (IFN-β1), IFN-α4, IL-6, and IL-12 was much lower in BMDCs
from wild-type mice (Tim-3+) than in those from Tim-3-deficient
mice (Tim-3−). Their findings suggest that Tim-3 signaling neg-
atively regulates the nucleic-acid-mediated anti-tumor immune
response of DCs (11). However, early data indicated that Tim-3
positively regulates DC activities. For example,Anderson et al. (12)
reported that Tim-3 is constitutively expressed on DCs and that
activation of Tim-3 signaling by Gal-9 or by an agonist Tim-3 anti-
body promotes LPS-induced DC activation. These findings suggest
a model in which Tim-3 promotes innate immunity (promotion).
Consistent with this report, Nagahara et al. (13) showed that, in
Meth-A tumor-bearing mice, Gal-9 increased the number of Tim-
3+ CD86+ mature DCs in vivo and prolonged survival, and that
depletion of Tim-3+ DCs from Gal-9-treated tumor-bearing mice
decreased anti-tumor immunity, indicating that Tim-3 expres-
sion on DCs plays a critical role in Gal-9-promoted anti-tumor
immunity. In addition, Kanzaki et al. (28) demonstrated that Gal-
9-Tim-3 signaling induced TNF-α production in cultured DCs in
a dose-dependent manner. Together, these data suggest that Tim-3
plays a dual role in regulating the activity of DCs.
However, other data do not support the idea that Tim-3 signal-
ing promotes the activity of DCs. If Tim-3 is a negative regulator
of the activation of T cells (1–4), macrophages (6, 7), and mono-
cytes (9), it is not clear why it would be a positive regulator of DC
activity (12, 13). Additionally, although Gal-9 induces DC acti-
vation, it does not necessarily do so by binding to Tim-3, as it
can bind to receptor(s) other than Tim-3 (29, 30). For example,
Kadowaki et al. (29) showed that Gal-9 increased the frequency
of CD11c (high) plasmacytoid DC-like macrophages in vitro in a
Tim-3-independent manner and prolonged the survival of lung
cancer-bearing mice. In addition, although previous reports sug-
gested that Tim-3 negatively regulates murine T cell responses (4)
and is upregulated on exhausted murine and human T cells, the
function of which can be restored by anti-Tim-3 antibodies (3, 4),
Leitner et al. (30) recently reported that the activation of human
T cells is not affected by anti-Tim-3 antibodies and that Tim-3 on
human T cells does not act as a receptor for Gal-9.
More investigations on the Tim-3 signaling pathway are needed
to clearly define the exact roles of Tim-3 in DCs. As a different
level of Tim-3 expression is seen on in vitro cultured DCs (28)
and tumor-derived DCs (10), the roles of Tim-3 in DCs might be
context-dependent. It is worth noting that Tim-3 overexpression
negatively regulates DC activity (10, 11), indicating that dysregu-
lated Tim-3 expression on DCs may also act as a marker of DC
dysfunction, as in to monocytes (8, 10, 18).
Tim-3 STIMULATES MAST CELLS TO PRODUCE Th2 CYTOKINES AND
REGULATES THE Th1/Th2 BALANCE IN VIVO
It is known that Tim-3 can negatively regulate the Th1 response by
inducing Th1 cell apoptosis (1). However, it has also been found
to regulate the Th2 cytokine response in experimental asthma.
Li et al. (31) showed that Tim-3 stimulated mast cells produced
Th2 cytokines and that anti-Tim-3 antibodies reduced asthmatic
inflammation. In agreement with this, Kearley et al. (32) found
that administration of anti-Tim-3 monoclonal antibodies before
each airway challenge in mice resulted in significantly reduced air-
way hyperreactivity, a decreased Th2 response, and an increased
Th1 response in the lung. Nakae et al. (33) reported that Tim-3
was constitutively expressed on mast cells and that, after IgE and
antigen stimulation, its expression was upregulated and enhanced
antigen-dependent Th2 cytokine secretion. The observations of
these three groups suggested that Tim-3 may influence T cell-
mediated immune responses, in part, by effects on mast cells.
Experiments were then performed to identify factor(s) that might
regulate Tim-3 expression on mast cells. Kim et al. (34) found that
Tim-3 mRNA levels were increased in the human mast cell line
HMC-1 following stimulation with TGF-β1, but not with IFN-α,
IFN-γ, TNF-α, or IL-10, and that the region −349 to +144 base
pairs relative to the transcription start site of the Tim-3 promoter
was crucial for basal and TGF-β1-induced Tim-3 promoter activ-
ity in these cells. In addition, Yoon et al. (35) reported that the
mitogen-activated protein kinase Erk kinase was involved in the
upregulation of Tim-3 transcription in Jurkat cells (a human T
cell line) stimulated with phorbol-12-myristate-13-acetate and in
HMC-1 cells stimulated with TGF-β. Frisancho-Kiss et al. (6) also
demonstrated that blockade of the Tim-3 pathway led to decreased
CD80 expression on mast cells and an enhanced inflammatory
response, showing that Tim-3 actively alters the phenotype and
activity of mast cells.
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Together, these data suggest that, by increasing the Th2
response while inhibiting the Th1 cytokine-induced inflamma-
tory response, Tim-3 signaling in mast cells influences the balance
of immune responses in vivo. However, the mechanism by which
the Tim-3 signaling pathway promotes Th2 cytokine production
in mast cells remains unclear.
Tim-3 ACTS AS AN NK CELL MATURATION MARKER AND IS
NECESSARY FOR THEIR CYTOTOXICITY, BUT ITS EXPRESSION IS
DYSREGULATED DURING CHRONIC VIRAL INFECTION
Recent data have shown that the activity of NK cells can also
be regulated by Tim-3 (14–16). NK cells are involved in innate
immunity and play an important protective role against viral
infection and cancer. This effect is achieved through a com-
plex mosaic of inhibitory and activating receptors expressed by
NK cells that ultimately determines the magnitude of the NK
cell response. Ndhlovu et al. (14) showed that many cytokines,
such as IFN-α and combinations of IL-12+IL-18 or IL-12+IL-
15, could induce Tim-3 upregulation on NK cells. Furthermore,
NK cell IFN-γ production and cytotoxic ability were associated
with the NK cells with the highest Tim-3 levels and these authors
therefore concluded that Tim-3 might act as a marker of fully
mature and functional NK cells. In agreement with these findings,
Gleason et al. (15) demonstrated that Tim-3 was upregulated on
human NK cells after activation and promoted IFN-γ production
in response to Gal-9. However, Ndhlovu et al. (14) demonstrated
that, when Tim-3 was cross-linked on NK cells with antibodies
or encountered target cells that expressed its ligand Gal-9, it sup-
pressed NK cell-mediated cytotoxicity, showing that Tim-3 also
suppresses NK cell functions. A study by Ju et al. (16) also sup-
ports a negative regulatory role of Tim-3 on the activity of NK
cells, as they showed that chronic hepatitis B infection upregu-
lated Tim-3 expression on NK cells and subsequently suppressed
NK cell function and that this process was reversed by blockade of
the Tim-3 pathway. These data suggest that Tim-3 has opposing
effects on NK cells. Although Tim-3 may be a marker of NK cell
activation, its overexpression may also restrain NK cell function in
certain situations (14, 16).
Recent data have also indicated that Tim-3 expression on NK
cells is dysregulated during chronic viral infection. For example,
Finney et al. (18) reported that Tim-3 was overexpressed on NK
cells isolated from patients with chronic untreated HIV infection
and that these cells were significantly less responsive to TLR stim-
ulation than cells from HIV(−) controls and that 6 months of
combination antiretroviral therapy resulted in partial restoration
of both Tim-3 levels and NK cell activation. These data show that
chronic HIV infection leads to increased Tim-3 expression on NK
cells and that this increased expression is associated with a dys-
function phenotype of NK cells. However, how, or to what extent,
the compromised responses of NK cells in chronic virus infections,
such as hepatitis B (16) and HIV(18, 36) infection, relate to Tim-3
expression requires further investigation. If Tim-3 is also a marker
of innate immune cell dysfunction in addition to being a marker
of CD4+ and CD8+ T cell dysfunction (2–4), dysregulated Tim-
3 expression may be associated with a more profound immune
deficit of both adaptive and innate immune cells.
Tim-3 EXPRESSION IS UPREGULATED ON THE ENDOTHELIUM IN
HUMANS OR MICE WITH LYMPHOMA AND ACTS AS AN INHIBITOR OF
CD4+ T CELLS
Wu et al. (37) showed that, in mice, Tim-3 is also expressed on
vascular endothelial cells (ECs), but does not function as a Gal-9
receptor on these cells, and, instead, mediates the interaction of
ECs with tumor cells or T cells. For example, Tim-3 on ECs, by
binding to a putative receptor on B16 tumor cells, resulting in
NF-κB activation, Bcl-2 and Bcl-xL upregulation, and Bax down-
regulation, which finally leads to tumor cell resistance to apoptosis.
They also reported that Tim-3 facilitates the survival of B16 cells in
the blood, increasing the number of metastatic nodules in the lung.
Thus, blockade of the Tim-3 pathway may help prevent metasta-
sis. Subsequently, using gene microarray analysis, Huang et al.
(38) showed that Tim-3 expression was significantly increased in
ECs from patients with lymphoma compared to ECs from con-
trols. They also showed that Tim-3 on ECs contributed to the
lymphoma endothelium-facilitated growth and dissemination of
lymphoma by interacting with circulating T cells and suppress-
ing the activation of CD4+ T cells. Moreover, Tim-3+ ECs were
found to suppress the activation of CD4+ T lymphocytes through
activation of the IL-6-STAT3 pathway and to inhibit Th1 polar-
ization, leading to tumor immune evasion. Their data suggest
that tissue cells expressing Tim-3 can also negatively regulate the
immune response by inhibiting the activity of T cells. Their find-
ings highlight a novel role of Tim-3 in tumor immune evasion,
providing further support for using Tim-3 as a therapeutic target
for tumors.
OTHER ROLES OF Tim-3 IN INNATE IMMUNITY
γδ T cells, or NKT cells, are considered to be one of the bridges
between innate and adaptive immunity. There are a few published
reports on the role of Tim-3 expression on γδ T cells or NKT
cells. In pregnant women with pre-eclampsia, decreased Tim-3
expression on γδ T cells was found to be associated with increased
IFN-γ production by these cells (39), suggesting that Tim-3 lim-
its γδ T cell activation. In addition, a negative correlation has
been observed between Tim-3 expression and TNF production by
NKT cells (40), suggesting a suppressive role of Tim-3 in NKT
functions.
T cell immunoglobulin and mucin domain protein-3 also
actively contributes to the homeostasis of innate immunity in
other ways. For example, Jayaraman et al. (41) showed that the
binding of Tim-3-Ig to cell-surface Gal-9, expressed by infected
macrophages, activated an antimicrobial program that restricts the
intracellular replication of M. tuberculosis. They further showed
that the Tim-3-Gal-9 interaction promoted macrophage clearance
of intracellular pathogens by inducing caspase-1-dependent IL-1β
secretion. In another report (42), Tim-3 was found to be involved
in the expansion of myeloid-derived suppressor cells (MDSCs).
Heterogeneous CD11b+Gr-1+ myeloid cells, which expand in
tumor-bearing individuals and in the presence of infection, are
potent suppressors of T cell responses (43). Dardalhon et al. (42)
reported that overexpression of Gal-9 under the control of the
actin promoter resulted in an increase in CD11b+Ly6G+ cells
and inhibition of immune responses. Additionally, knock out
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FIGURE 2 | Summary ofTim-3 expression on different innate immune
cell populations and its functions. (A)Tim-3 acts as an activation marker
of macrophages and a suppressor of macrophage activity. Tim-3 expression
on macrophages is upregulated following activation (e.g., by LPS). High
Tim-3 expression contributes to the homeostasis of macrophages, as
blockade of the Tim-3 pathway leads to excessive macrophage activation.
(B)Tim-3 acts as both an activation marker of monocytes and a suppressor
of monocyte activity. Tim-3 is constitutively expressed on monocytes at
high levels. Tim-3 expression decreases rapidly following stimulation of
TLRs and this decrease correlates with increased monocyte activation.
However, during chronic viral infection, Tim-3 is overexpressed on
monocytes or cannot be downregulated, leading to the dysfunction or
exhaustion of monocytes. (C)The roles of Tim-3 in dendritic cells are
context-dependent. In in vitro cultured DCs, Tim-3 signaling promotes DC
responses by increasing TNF-α production (C1), while, in tumor-infiltrating
DCs, it inhibits the TLR3-, TLR7-, and TLR9-mediated anti-tumor effects of
DCs (C2). (D)Tim-3 signaling in mast cells promotes Th2 responses by
(Continued)
FIGURE 2 | Continued
increasing IL-4, IL-5, and IL-13 production. (E) Expression ofTim-3 on NK cells
is increased following activation and these increased Tim-3 levels act as a
marker of fully mature and functional NK cells, but also potentially restrain
NK cell function. During chronic viral infection, Tim-3 is overexpressed on
NK cells or cannot be downregulated, both of which compromise NK cell
function. (F)Tim-3 expression on the vascular endothelium is increased in
the tumor microenvironment of lymphoma and melanoma, resulting in
inhibition of Th1 cell function and increased tumor metastasis.
of Tim-3 reduced numbers of CD11b+Ly6G+ cells, while trans-
genic mice overexpressing Tim-3 showed accelerated growth of
EL4 lymphoma and an increased frequency of MDSCs in the
spleen compared to wild-type mice. Ji et al. (44) demonstrated
that HCV-infected human hepatocytes showed increased Tim-3
expression and, when co-cultured with human CD4+ T cells, drove
their conversion to CD25+Foxp3+ Treg cells. These data demon-
strate that binding of Gal-9 to Tim-3 can also inhibit immune
responses by regulating the expansion of immune suppressor
cells.
Tim-3 expression on different innate immune cells and its
functions are summarized in Figure 2.
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
From the evidence presented in this article, it is clear that Tim-3
contributes to immune homeostasis by maintaining optimal acti-
vation of innate immune cells. Due to the association between
dysregulated Tim-3 expression on innate immune cells and the
pathogenesis of tumors and chronic viral infections, it is important
to determine the detailed mechanisms regulating Tim-3 expres-
sion on different innate immune cells. In addition, although
it is known that Tim-3 signaling negatively regulates the acti-
vation of innate immune cells, in most cases, the nature of
the downstream signaling pathways in the different cell types
is not known. The available evidence suggests that Tim-3 may
be an attractive target for clinical intervention, and address-
ing the remaining questions should be a major focus of future
studies.
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